Idorsia publishes end results of repurchase offer for its 2025 and 2028 convertible bonds

Core Points - Idorsia Ltd has announced the results of its repurchase offer for outstanding convertible bonds totaling CHF 204 million maturing in 2025 and CHF 600 million maturing in 2028 [1][2] - The repurchase offer for the 2025 bonds saw an acceptance rate of 91.90%, with bondholders accepting an aggregate nominal value of CHF 187,476,000, while the 2028 bonds had a 94.53% acceptance rate with CHF 567,200,000 accepted [2] - The settlement of the repurchase offer is expected to occur on August 26, 2025, pending the satisfaction or waiver of certain conditions [3] Company Overview - Idorsia aims to challenge established medical paradigms by discovering, developing, and commercializing transformative medicines, evolving into a leading biopharmaceutical company [5] - The company is headquartered near Basel, Switzerland, and has a strong focus on small-molecule drugs, with a promising in-house development pipeline and partnerships to enhance portfolio value [6]